Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A new oral combo for a tough-to-treat breast cancer just got the green light. The FDA approved giredestrant (Wilserdly) plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer — the latest in a wave of ESR1-targeted approvals. The phase 3 evERA trial showed a 62% reduction in disease progression or death compared to standard endocrine therapy.
The FDA has approved giredestrant (Wilserdly, Genentech) in combination with everolimus for adults with estrogen receptor–positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. The indication covers patients whose disease progressed during or after endocrine-based adjuvant therapy, or following endocrine-based therapy in the metastatic setting. The FoundationOne Liquid CDx assay was simultaneously authorized as a companion diagnostic to identify eligible patients.
The approval is backed by data from the phase 3 evERA Breast Cancer trial, which enrolled 373 adults — 207 of whom had ESR1-mutated tumors. Among those patients, giredestrant plus everolimus cut the risk of disease progression or death by 62% compared to physician's choice of endocrine therapy. Giredestrant is a fully oral selective ER degrader (SERD), offering a convenient targeted option for patients with limited choices after prior endocrine therapy failure.
By the Numbers:
Why it matters: ESR1 mutations emerge in roughly 40% of patients who progress on endocrine therapy, driving resistance to aromatase inhibitors. This fully oral regimen directly targets a key genomic driver of resistance, offering patients a meaningful new path to prolonged disease control.